Study guide
6.3 Hypertensive Emergencies and Arrhythmias
Board Certified Critical Care Pharmacist Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pathophysiology and Recognition of Critical Illness
1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness
2 Chapter 2: Medical Devices and Circulatory Support
2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care
3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management
3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation
4 Chapter 4: Vasoactive and Inotropic Therapy in Shock
4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock
5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)
5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness
6 Chapter 6: Cardiovascular Emergencies
6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias
7 Chapter 7: Pulmonary and Infectious Diseases in the ICU
7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU
8 Chapter 8: Neurocritical Care
8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury
9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies
9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy
10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition
10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral
11 Chapter 11: Quality, Safety, and Clinical Guidelines
11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions
12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine
12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management
13 Chapter 13: Treatment Planning and Care Coordination
13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education
6.3 Hypertensive Emergencies and Arrhythmias
Key Takeaways Explain This Topic AI
A hypertensive emergency is defined by severely elevated blood pressure coupled with evidence of acute, ongoing target organ damage; it dictates immediate IV therapy, whereas hypertensive urgency does not.
The target for blood pressure reduction in hypertensive emergencies depends entirely on the specific organ damage (e.g., rapid and severe reduction in aortic dissection vs. permissive hypertension in acute ischemic stroke).
Amiodarone is a versatile and commonly used antiarrhythmic in the ICU, effective for both atrial and ventricular arrhythmias, but requires monitoring for hypotension during initial IV administration.
Unstable patients with tachyarrhythmias (causing shock, ischemic chest pain, or altered mental status) require immediate synchronized electrical cardioversion.
Last updated: July 2026
Hypertensive Emergencies and Arrhythmias
Critically ill patients frequently experience severe hemodynamic derangements. Managing profound hypertension and complex arrhythmias requires a nuanced understanding of cardiovascular pharmacology and the specific physiological demands of the underlying pathology.
Hypertensive Emergencies vs. Urgencies
Severe hypertension (typically defined as systolic BP > 180 mmHg and/or diastolic BP > 120 mmHg) is a common clinical scenario. The critical distinction lies in the presence or absence of target organ damage.
Hypertensive Urgency: Severe hypertension without evidence of acute, progressive target organ damage. These patients can often be managed with oral antihypertensives, aiming for a gradual reduction in blood pressure over 24 to 48 hours to avoid hypoperfusion of vital organs.
Hypertensive Emergency: Severe hypertension accompanied by acute, progressive target organ damage . Examples include acute pulmonary edema, acute myocardial infarction, acute aortic dissection, hypertensive encephalopathy, acute ischemic stroke, or acute kidney injury. This requires admission to the ICU and immediate administration of titratable intravenous antihypertensive agents.
Condition-Specific Blood Pressure Targets
In most hypertensive emergencies, the general rule is to lower the mean arterial pressure (MAP) by no more than 20-25% in the first hour to prevent ischemic damage to the brain, heart, and kidneys, which have adapted to higher pressures. However, there are critical exceptions where treatment must be tailored to the specific diagnosis:
1. Acute Aortic Dissection
This is the most time-critical hypertensive emergency. The goal is to rapidly reduce sheer stress on the aortic wall (dP/dt).
Target: Reduce systolic BP to < 120 mmHg and heart rate to < 60 bpm within 20 minutes.
Therapy: Beta-blockade is the absolute first step to prevent reflex tachycardia when vasodilators are used. Esmolol or labetalol are preferred. Once the heart rate is controlled, a vasodilator like nitroprusside or nicardipine can be added.
2. Acute Ischemic Stroke
In acute ischemic stroke, perfusion to the ischemic penumbra relies on systemic blood pressure. Lowering the BP too aggressively can expand the size of the infarction.
Target (Not receiving tPA): Permissive hypertension. Do not treat unless BP > 220/120 mmHg. If treatment is needed, lower by 15% in the first 24 hours.
Target (Receiving tPA): BP must be lowered to < 185/110 mmHg prior to administering fibrinolytics and maintained < 180/105 mmHg for 24 hours post-infusion to prevent hemorrhagic conversion.
Therapy: Labetalol, nicardipine, or clevidipine.
3. Acute Pulmonary Edema
Hypertension drives increased afterload, exacerbating fluid backup into the lungs.
Target: Rapidly reduce preload and afterload to relieve symptoms.
Therapy: Intravenous nitroglycerin is the agent of choice. Nitroprusside is an alternative for severe afterload reduction. Avoid beta-blockers, as they decrease cardiac contractility.
Arrhythmias in the ICU
Arrhythmias in the ICU are often secondary to underlying stressors such as electrolyte imbalances (hypokalemia, hypomagnesemia), hypoxemia, ischemia, acidosis, or the administration of arrhythmogenic drugs (e.g., vasopressors, inotropes).
General Approach to Tachyarrhythmias
The fundamental branch point in managing any tachyarrhythmia is assessing the patient's hemodynamic stability.
Unstable: (Defined by hypotension, altered mental status, signs of shock, ischemic chest pain, or acute heart failure). The treatment for an unstable tachyarrhythmia is immediate synchronized electrical cardioversion (or defibrillation if pulseless VF/VT).
Stable: If the patient is stable, a 12-lead ECG should be obtained to evaluate the rhythm, focusing on whether the QRS complex is narrow or wide, and whether the rhythm is regular or irregular.
Atrial Fibrillation (AFib)
New-onset AFib is the most common arrhythmia in the ICU. Management focuses on rate control, rhythm control, and anticoagulation.
Rate Control: The preferred initial strategy for stable patients. Agents include beta-blockers (e.g., metoprolol), non-dihydropyridine calcium channel blockers (e.g., diltiazem), or digoxin. Diltiazem and metoprolol must be used with caution in patients with reduced ejection fraction.
Rhythm Control: Attempted if the patient remains highly symptomatic or hemodynamically compromised despite rate control. Amiodarone is the most commonly used agent in the ICU for pharmacological cardioversion or maintenance of sinus rhythm.
Ventricular Tachycardia (VT)
VT is a wide-complex tachycardia that can rapidly degenerate into ventricular fibrillation.
Pulseless VT: Treat as cardiac arrest. Immediate CPR and defibrillation.
Unstable VT (with a pulse): Immediate synchronized cardioversion.
Stable VT: Pharmacological therapy is initiated. Intravenous amiodarone is the first-line agent. Alternatives include procainamide or lidocaine. It is crucial to correct underlying electrolyte derangements, particularly potassium and magnesium.
Pharmacological Agents
Amiodarone: A Class III antiarrhythmic, though it has properties of all four classes. Extremely effective for both atrial and ventricular arrhythmias. A common side effect of IV loading is hypotension, driven by the diluent (polysorbate 80) rather than the drug itself.
Procainamide: A Class Ia antiarrhythmic. Effective for stable VT. Administration must be monitored closely for widening of the QRS complex, QTc prolongation, and hypotension.
Adenosine: Used for the acute termination of regular, narrow-complex supraventricular tachycardias (SVT). It causes transient AV nodal block. It has an extremely short half-life (< 10 seconds) and must be pushed rapidly via a proximal IV site.
Clinical Scenario
A 58-year-old male with a history of hypertension presents to the ED complaining of "tearing" chest pain radiating to his back. His blood pressure is 210/120 mmHg in his right arm and 180/100 mmHg in his left arm. His heart rate is 115 bpm. A CT angiogram confirms a Stanford Type B aortic dissection.
Management: This is a classic hypertensive emergency requiring immediate action to reduce aortic wall stress. The initial step is to control the heart rate and block reflex tachycardia. An intravenous beta-blocker, such as an esmolol infusion, should be started first, aiming for a heart rate < 60 bpm. Once the heart rate is controlled, an intravenous vasodilator (like nicardipine or nitroprusside) should be added to rapidly lower the systolic blood pressure to < 120 mmHg. Administering a vasodilator before a beta-blocker is contraindicated, as the resulting reflex tachycardia increases aortic wall shear stress and can propagate the dissection.